The primary objective is to assess with the PPQ questionnaire the patient preference for Wynzora compared with therapy carried out previously with Enstilar spray foam. Secondary objectives Assess satisfaction with the treatment. Assess adherence to therapy. Evaluate the impact of various clinical and demographic factors on treatment adherence. Evaluate the efficacy of Wynzora cream therapy.

Inclusion Criteria:

• Patients older than 18 years of age, of either sex;
• Patients diagnosed with mild-to-moderate psoriasis (PASI and BSA <10) requiring monotherapy topical with Wynzora;
• Patients who have stopped treatment with Enstilar foam for any reason for at least 30 days; and
• Patients whose medical records are accessible and record all demographic parameters, anthropometric and clinical parameters during the treatment period
• Signature of written informed consent;

Exclusion Criteria:

• Patients with palmoplantar, inverse, erythrodermic, guttate, and scalp psoriasis.
• Patients who are taking concomitant systemic therapies for psoriasis, such as. cyclosporine, methotrexate, acitretin, phototherapy or biologic therapies.
• Women who are pregnant or planning to become pregnant.
• Patients with disabilities or other motor problems that could complicate self-medication.

Patients diagnosed with psoriasis will be enrolled, who will be according to clinical practice will be prescribed treatment with Wynzora cream for 30 consecutive days, referring to the Dermatology and Venereology outpatient clinics of the Fondazione Policlinico Universitario A. Gemelli, IRCCS Rome